Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
Replimune price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Replimune's price to book ratio was 17.3× on Nov 11, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 0.9× to 17.3×, with a median of 2.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.3× | +14.4 |
| 2025 | Dec 31, 2025 | 2.9× | +0.7 |
| 2024 | Dec 31, 2024 | 2.2× | +1.1 |
| 2023 | Dec 29, 2023 | 1.1× | −2.5 |
| 2022 | Dec 30, 2022 | 3.5× | +0.7 |
| 2021 | Dec 31, 2021 | 2.8× | −3.1 |
| 2020 | Dec 31, 2020 | 5.9× | +2.1 |
| 2019 | Dec 31, 2019 | 3.8× | +1.7 |
| 2018 | Dec 31, 2018 | 2.1× | – |
See a number that looks wrong?